Literature DB >> 8409933

Analysis of endoproteolytic cleavage and intracellular transport of human immunodeficiency virus type 1 envelope glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic reticulum retention signal.

N U Raja1, M J Vincent, M A Jabbar.   

Abstract

We investigated endoproteolytic processing of the human immunodeficiency virus (HIV) envelope glycoprotein precursor, gp160, as well as envelope-mediated membrane fusion in the presence of CD4 molecules that were either partially or fully retained in the endoplasmic reticulum (ER). Pulse-chase analyses revealed that gp160 formed complexes with CD4 molecules, and gp160 in the complex was endoproteolytically cleaved to gp120 and gp41 in the secretory pathway. The gp120/gp41 complex thus generated was properly targeted to the plasma membrane in cells expressing gp160 and wild-type CD4 or mutant CD4 molecules that were partially retained in the ER. Additionally, membrane fusion (syncytium) assays were performed to monitor the presence or absence of gp120/gp41 complexes at the cell surface of cotransfected cells and demonstrated that the HIV-1 envelope glycoprotein-mediated membrane fusion was appreciably reduced in the presence of wild-type CD4 or either one of the mutant CD4 molecules. Reduction in the formation of syncytia appears to be due predominantly to saturation of the CD4 binding site on the gp120/gp41 complex at the cell surface of cotransfected cells, but partial retention of the complex in the ER could also partly account for the reduction. However, the intracellular gp120/gp41 complex generated in cells expressing gp160 and CD4 mutant having the transmembrane ER retention signal (KKTC) was completely retained in the ER and hence could not participate in membrane fusion events at the plasma membrane. Taken together, these data suggest that the endoproteolytic cleavage of gp160 occurs in the ER or cis-Golgi network, and ER retention strategies can potentially be used in preventing the spread of HIV-1 infection in permissive cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8409933     DOI: 10.1099/0022-1317-74-10-2085

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus.

Authors:  M J Schnell; L Buonocore; E Boritz; H P Ghosh; R Chernish; J K Rose
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

3.  Ubiquitination of the human immunodeficiency virus type 1 env glycoprotein.

Authors:  A Bültmann; J Eberle; J Haas
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells.

Authors:  M Paul; S Mazumder; N Raja; M A Jabbar
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Measuring HIV fusion mediated by envelopes from primary viral isolates.

Authors:  Marielle Cavrois; Jason Neidleman; Nicole Galloway; Cynthia A Derdeyn; Eric Hunter; Warner C Greene
Journal:  Methods       Date:  2010-06-08       Impact factor: 3.608

Review 6.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

7.  Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules.

Authors:  Luis R Miranda; Brian C Schaefer; Abraham Kupfer; Zixin Hu; Alex Franzusoff
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.